# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest signifi...
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in ag...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by whic...
Medtronic Plc (NYSE: MDT) says the FDA Circulatory System Devices Panel (CSDP) voted unanimously (13-0) on safety and in favor ...
The FDA's Circulatory Systems Devices Panel of the Medical Devices Advisory Committee backed Recor Medical Inc and its pare...
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H.
Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Ka...
Here's a roundup of top developments in the biotech space over the last 24 hours: